Compare PCLA & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCLA | NEUP |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Building Products | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 10.3M |
| IPO Year | 2025 | N/A |
| Metric | PCLA | NEUP |
|---|---|---|
| Price | $0.33 | $3.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 60.1M | 76.0K |
| Earning Date | 02-13-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,065,197.00 | ★ $15,649,448.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.26 | N/A |
| 52 Week Low | $0.12 | $3.00 |
| 52 Week High | $9.80 | $21.40 |
| Indicator | PCLA | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 42.28 |
| Support Level | $0.29 | $3.65 |
| Resistance Level | $0.35 | $3.91 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 55.78 | 58.42 |
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.